论文部分内容阅读
医保支付标准不仅改变支付形式,关键点在“调动医院降低药价的积极性”。因此,医院有动力跟药企认真谈判,其实力及专业能力都比招标办和人社部更胜一筹。这似乎就是升级版的二次议价,多数仿制药将受到影响。在医保支付标准规定下,定点机构可以留存药品实际销售价和医保支付标准间的差额。对此,各地将有不同规定,有的地方可以直接留存医院,有的地方要上交财政后再视情况补贴给医院。这使得定点机构在采购药品上更有动力向
Medicare payment standards not only change the form of payment, the key point in the “transfer of hospital incentives to reduce drug prices.” Therefore, the hospital has the power to seriously negotiate with the pharmaceutical companies, its strength and professional ability than the tender Office and the Ministry of Humanitarian Affairs superior. This seems to be an upgraded version of the second bargain, most generic drugs will be affected. Under the medical insurance payment standards, the designated agencies can keep the difference between the actual sales price of the drugs and the standard of medical insurance payment. In this regard, different places will have different provisions, some places can be directly retained in the hospital, and some places to be turned over to finance the case after the subsidy to the hospital. This makes the pointing mechanism even more motivating for purchasing drugs